BMY Pipeline Math: $25B Target, $12B Cliff, Tight Window

Bristol Myers Squibb (BMY) has a pipeline story that looks real on paper. The company is betting on a wave of new drug launches – Breyanzi, Opdualag, Sotyktu, Camzyos – to replace revenue lost to patent expirations on Revlimid and Eliquis. The math works if the launches hit their peak-sales targets. The problem is the timing.

BMY shares have rallied 24% since September, partly on pipeline optimism and partly on a broader rotation into value-oriented healthcare names. The stock still trades at roughly 8.5x forward earnings, a discount to the sector that reflects the revenue cliff ahead. Revlimid alone lost about $4 billion in sales last year as generic competition accelerated. Eliquis faces a similar erosion window starting in 2028.

The bull case rests on execution. Breyanzi, a CAR-T therapy, posted $364 million in sales last quarter, up 50% year over year. Opdualag, a fixed-dose combination for melanoma, grew 42% to $213 million. Sotyktu, a psoriasis drug, hit $80 million. Those are real growth numbers. They are still small relative to the roughly $12 billion in combined annual revenue from Revlimid and Eliquis. The gap is wide.

Management has been clear about the path. At the company's investor day in December, executives laid out a target of $25 billion in new-product revenue by 2030. That would require the pipeline to deliver roughly $15 billion in incremental sales over the next six years. The FDA approval calendar over the next 12 months includes a handful of high-stakes decisions: a label expansion for Breyanzi in earlier lines of lymphoma, a filing for the oral TYK2 inhibitor in lupus, and a readout for the KRAS G12D program in pancreatic cancer. Each one moves the needle if it hits.

The near-term financials are under pressure. BMY reported fourth-quarter revenue of $11.4 billion, down 2% from a year earlier, as Revlimid sales fell 23%. Adjusted earnings per share came in at $1.70, a nickel below consensus. The company guided 2025 revenue in the range of $44.5 billion to $46.5 billion, implying flat to slightly negative top-line growth. Margins are also tightening. The gross margin slipped to 74% from 76% a year ago, partly on product mix and partly on higher manufacturing costs for the newer biologics.

The balance sheet is manageable. Net debt stands at roughly $13 billion, and the company generates about $10 billion in annual free cash flow. The dividend, yielding 4.7%, is well covered. The buyback has slowed. BMY repurchased $1.2 billion in shares last year, down from $3.4 billion in 2023. The company is preserving cash to fund pipeline investments and potential bolt-on acquisitions.

The risk is that the pipeline delivers slower than expected, or that one of the key trials misses. A negative readout in the KRAS program would remove a $3 billion peak-sales opportunity from the model. That would leave BMY with a narrower path to replacing the Revlimid and Eliquis revenue. The stock would likely re-rate lower.

The counterargument is that the market is already pricing in some of that risk. The 8.5x multiple is not a growth-stock valuation. If the pipeline hits even 80% of management's targets, the earnings power in 2030 could support a meaningfully higher stock price. The question is whether investors have the patience to wait through two to three years of flat revenue and margin compression.

AlphaScala's BMY stock page shows a score of 61 out of 100, a Moderate rating. That reflects the tension between the pipeline upside and the near-term earnings drag. For now, the stock is a bet on the science and the calendar. The next 12 months will tell whether the bet pays off.